As MHC class II prediction methods continue to be optimized, for example, by using highly sensitive molecular identification methods employing CIITA to drive MHC II expression on patient-derived cancer cells,48,63 the incorporation of CD4+ T cell antigens into personalized cancer vaccines should become feasible.64 Here, CD4 is linked to cancer.